Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes

American Journal of Cardiology

Volumn 101, Issue 9, 2008, Pages 1226-1231

  Iijima, Raisuke ^a   Ndrepepa, Gjin ^a   Mehilli, Julinda ^a   Dirschinger, Josef ^b   Pache, Jürgen ^a   Seyfarth, Melchior ^a   Schömig, Albert ^a,b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS;

ACUTE CORONARY SYNDROME; AGED; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 43049145440     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.12.019     Document Type: Article

References (29)

1. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., Neumann F.J., Robertson D.H., DeLucca P.T., DiBattiste P.M., Gibson C.M., and Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354 (1999) 708-715
3. Schömig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., Walter H., Zitzmann-Roth E.M., Richardt G., Alt E., Schmitt C., and Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
4. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., and Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
5. Kastrati A., Mehilli J., Schuhlen H., Dirschinger J., Dotzer F., ten Berg J.M., Neumann F.J., Bollwein H., Volmer C., Gawaz M., Berger P.B., and Schömig A. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
6. Lincoff A.M., Califf R.M., Moliterno D.J., Ellis S.G., Ducas J., Kramer J.H., Kleiman N.S., Cohen E.A., Booth J.E., Sapp S.K., Cabot C.F., and Topol E.J. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 341 (1999) 319-327
7. Marso S.P., Lincoff A.M., Ellis S.G., Bhatt D.L., Tanguay J.F., Kleiman N.S., Hammoud T., Booth J.E., Sapp S.K., and Topol E.J. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 100 (1999) 2477-2484
8. Stone G.W., Grines C.L., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J., Guagliumi G., Stuckey T., Turco M., Carroll J.D., Rutherford B.D., and Lansky A.J. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
9. Kastrati A., Mehilli J., Neumann F.J., Dotzer F., ten Berg J., Bollwein H., Graf I., Ibrahim M., Pache J., Seyfarth M., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
10. Schühlen H., Kastrati A., Mehilli J., Hausleiter J., Dirschinger J., Dotzer F., Bollwein H., and Schömig A. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT-a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Am Heart J 151 (2006) 1248-1254
11. Ellis S.G., Vandormael M.G., Cowley M.J., DiSciascio G., Deligonul U., Topol E.J., and Bulle T.M. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82 (1990) 1193-1202
12. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
13. Hausleiter J., Kastrati A., Mehilli J., Schuhlen H., Pache J., Dotzer F., Glatthor C., Siebert S., Dirschinger J., and Schömig A. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 256 (2004) 388-397
14. Mehilli J., Kastrati A., Schuhlen H., Dibra A., Dotzer F., von Beckerath N., Bollwein H., Pache J., Dirschinger J., Berger P.P., and Schömig A. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110 (2004) 3627-3635
15. Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., Boulenc J.M., Morice M.C., Maillard L., Pansieri M., Choussat R., and Pinton P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
16. Tcheng J.E., Kandzari D.E., Grines C.L., Cox D.A., Effron M.B., Garcia E., Griffin J.J., Guagliumi G., Stuckey T., Turco M., et al., CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 108 (2003) 1316-1323
17. Le Breton H., Plow E.F., and Topol E.J. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 28 (1996) 1643-1651
18. Schwartz R.S., Holmes Jr. D.R., and Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 20 (1992) 1284-1293
19. Romagnoli E., Burzotta F., Trani C., Biondi-Zoccai G.G., Giannico F., and Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 23 (2007) 57-63
20. Tam S.H., Sassoli P.M., Jordan R.E., and Nakada M.T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 98 (1998) 1085-1091
21. Nurden A.T., Poujol C., Durrieu-Jais C., and Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol 19 (1999) 2835-2840
22. Stouffer G.A., Hu Z., Sajid M., Li H., Jin G., Nakada M.T., Hanson S.R., and Runge M.S. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 97 (1998) 907-915
23. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., and Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
24. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., Dudek D., Fort S., Schiele F., Zmudka K., Guagliumi G., and Russell M.E. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
25. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
26. Lansky A.J., Costa R.A., Mintz G.S., Tsuchiya Y., Midei M., Cox D.A., O'Shaughnessy C., Applegate R.A., Cannon L.A., Mooney M., et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109 (2004) 1948-1954
27. Teirstein P.S., Kao J., Watkins M., Tannenbaum M.A., Laufer N., Chang M., Mehran R., Dangas G., Russell M.E., Ellis S.G., and Stone G.W. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol 96 (2005) 500-505
28. Ndrepepa G., Kastrati A., Mehilli J., Neumann F.J., ten Berg J., Bruskina O., Dotzer F., Seyfarth M., Pache J., Dirschinger J., et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 114 (2006) 2040-2046
29. Mehilli J., Ndrepepa G., Kastrati A., Neumann F.J., ten Berg J., Bruskina O., Dotzer F., Seyfarth M., Pache J., Kufner S., et al. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. Am Heart J 154 (2007) 158 e1-e7